Zobrazeno 1 - 10 of 199 pro vyhledávání: '"Reger De Moura C"'
1
Akademický článek
Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models.
Autor: Louveau B; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), Paris, France., Reger De Moura C; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), Paris, France., Jouenne F; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), Paris, France., Sadoux A; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), Paris, France., Allayous C; Department of Dermatology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France., Da Meda L; Department of Dermatology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France., Bernard-Cacciarella M; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), Paris, France., Baroudjian B; Department of Dermatology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France., Lebbé C; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), Paris, France.; Department of Dermatology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France., Mourah S; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), Paris, France., Dumaz N; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), Paris, France.
Publikováno v: Melanoma research [Melanoma Res] 2024 Apr 01; Vol. 34 (2), pp. 186-192. Date of Electronic Publication: 2023 Dec 22.
Zobrazit plný text záznamu
2
Akademický článek
PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors.
Autor: Delyon J; Human Immunology Pathophysiology & Immunotherapy (HIPI), Université Paris Cité, INSERM U976 - Hôpital Saint Louis - 1 avenue Claude Vellefaux, Paris, 75010, France.; Université Paris Cité, AP-HP Dermato-oncology and CIC, Cancer institute APHP.nord Paris Cité, INSERM U976, Saint Louis Hospital, Paris, F-75010, France., Becherirat S; Human Immunology Pathophysiology & Immunotherapy (HIPI), Université Paris Cité, INSERM U976 - Hôpital Saint Louis - 1 avenue Claude Vellefaux, Paris, 75010, France., Roger A; Human Immunology Pathophysiology & Immunotherapy (HIPI), Université Paris Cité, INSERM U976 - Hôpital Saint Louis - 1 avenue Claude Vellefaux, Paris, 75010, France., Bernard-Cacciarella M; Human Immunology Pathophysiology & Immunotherapy (HIPI), Université Paris Cité, INSERM U976 - Hôpital Saint Louis - 1 avenue Claude Vellefaux, Paris, 75010, France.; Université Paris Cité, AP-HP Dermato-oncology and CIC, Cancer institute APHP.nord Paris Cité, INSERM U976, Saint Louis Hospital, Paris, F-75010, France., Reger De Moura C; Human Immunology Pathophysiology & Immunotherapy (HIPI), Université Paris Cité, INSERM U976 - Hôpital Saint Louis - 1 avenue Claude Vellefaux, Paris, 75010, France.; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, F-75010, France., Louveau B; Human Immunology Pathophysiology & Immunotherapy (HIPI), Université Paris Cité, INSERM U976 - Hôpital Saint Louis - 1 avenue Claude Vellefaux, Paris, 75010, France.; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, F-75010, France., Mourah S; Human Immunology Pathophysiology & Immunotherapy (HIPI), Université Paris Cité, INSERM U976 - Hôpital Saint Louis - 1 avenue Claude Vellefaux, Paris, 75010, France.; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, F-75010, France., Lebbé C; Human Immunology Pathophysiology & Immunotherapy (HIPI), Université Paris Cité, INSERM U976 - Hôpital Saint Louis - 1 avenue Claude Vellefaux, Paris, 75010, France.; Université Paris Cité, AP-HP Dermato-oncology and CIC, Cancer institute APHP.nord Paris Cité, INSERM U976, Saint Louis Hospital, Paris, F-75010, France., Dumaz N; Human Immunology Pathophysiology & Immunotherapy (HIPI), Université Paris Cité, INSERM U976 - Hôpital Saint Louis - 1 avenue Claude Vellefaux, Paris, 75010, France. nicolas.dumaz@inserm.fr.
Publikováno v: Cell communication and signaling : CCS [Cell Commun Signal] 2024 Nov 21; Vol. 22 (1), pp. 559. Date of Electronic Publication: 2024 Nov 21.
Zobrazit plný text záznamu
3
Akademický článek
Inactivation of kindlin-3 increases human melanoma aggressiveness through the collagen-activated tyrosine kinase receptor DDR1.
Autor: Reger De Moura C; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France.; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France., Louveau B; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France.; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France., Jouenne F; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France.; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France., Vilquin P; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France., Battistella M; Department of Pathology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France., Bellahsen-Harrar Y; Department of Pathology, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France., Sadoux A; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France., Menashi S; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France.; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France., Dumaz N; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France., Lebbé C; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France.; Department of Dermatology and CIC, Hôpital Saint Louis, Cancer Institute, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France., Mourah S; Department of Pharmacology and Tumor Genomics, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, F-75010, Paris, France. samia.mourah@aphp.fr.; Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010, Paris, France. samia.mourah@aphp.fr.
Publikováno v: Oncogene [Oncogene] 2024 May; Vol. 43 (21), pp. 1620-1630. Date of Electronic Publication: 2024 Apr 03.
Zobrazit plný text záznamu
6
Akademický článek
A-387 - Discoidin domain receptor 1, a melanoma immunomodulator
Autor: Lutz, C., Lourenço, A., Reger de Moura, C., Louveau, B., Marie-Cardine, A., Lebbé, C., Mourah, S.
Publikováno v: In EJC Skin Cancer 2024 2 Supplement 1
Zobrazit plný text záznamu
7
Akademický článek
Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction.
Autor: Landras A; Inserm, UMR_S976, Université de Paris, F-75010, Paris, France., Reger de Moura C; Inserm, UMR_S976, Université de Paris, F-75010, Paris, France.; Pharmacogenomics Department, Hopital Saint Louis, AP-HP, F-75010, Paris, France., Villoutreix BO; Inserm, UMR_S1141, Hopital Robert Debré, F-75019, Paris, France., Battistella M; Inserm, UMR_S976, Université de Paris, F-75010, Paris, France.; Pathology Department, Hopital Saint Louis, AP-HP, F-75010, Paris, France., Sadoux A; Pharmacogenomics Department, Hopital Saint Louis, AP-HP, F-75010, Paris, France., Dumaz N; Inserm, UMR_S976, Université de Paris, F-75010, Paris, France., Menashi S; Pharmacogenomics Department, Hopital Saint Louis, AP-HP, F-75010, Paris, France., Fernández-Recio J; Instituto de Ciencias de la Vid y del Vino (ICVV), CSIC-Universidad de La Rioja-Gobierno de La Rioja, Logroño, Spain., Lebbé C; Inserm, UMR_S976, Université de Paris, F-75010, Paris, France.; Dermatology Department, Hopital Saint Louis, AP-HP, F-75010, Paris, France., Mourah S; Inserm, UMR_S976, Université de Paris, F-75010, Paris, France. samia.mourah@aphp.fr.; Pharmacogenomics Department, Hopital Saint Louis, AP-HP, F-75010, Paris, France. samia.mourah@aphp.fr.
Publikováno v: Oncogene [Oncogene] 2022 Apr; Vol. 41 (15), pp. 2254-2264. Date of Electronic Publication: 2022 Feb 26.
Zobrazit plný text záznamu
8
Akademický článek
TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro.
Autor: Delyon J; INSERM, U976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010 Paris, France.; Université Paris Cité, Institut de Recherche Saint Louis (IRSL), F-75010 Paris, France.; Département de Dermatologie, Hôpital Saint Louis, AP-HP, F-75010 Paris, France., Vallet A; INSERM, U976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010 Paris, France.; Université Paris Cité, Institut de Recherche Saint Louis (IRSL), F-75010 Paris, France., Bernard-Cacciarella M; INSERM, U976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010 Paris, France.; Université Paris Cité, Institut de Recherche Saint Louis (IRSL), F-75010 Paris, France.; Département de Dermatologie, Hôpital Saint Louis, AP-HP, F-75010 Paris, France., Kuzniak I; INSERM, U976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010 Paris, France.; Université Paris Cité, Institut de Recherche Saint Louis (IRSL), F-75010 Paris, France., Reger de Moura C; INSERM, U976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010 Paris, France.; Université Paris Cité, Institut de Recherche Saint Louis (IRSL), F-75010 Paris, France.; Département de Pharmacogénomique, Hôpital Saint Louis, AP-HP, F-75010 Paris, France., Louveau B; INSERM, U976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010 Paris, France.; Université Paris Cité, Institut de Recherche Saint Louis (IRSL), F-75010 Paris, France.; Département de Pharmacogénomique, Hôpital Saint Louis, AP-HP, F-75010 Paris, France., Jouenne F; INSERM, U976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010 Paris, France.; Université Paris Cité, Institut de Recherche Saint Louis (IRSL), F-75010 Paris, France.; Département de Pharmacogénomique, Hôpital Saint Louis, AP-HP, F-75010 Paris, France., Mourah S; INSERM, U976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010 Paris, France.; Université Paris Cité, Institut de Recherche Saint Louis (IRSL), F-75010 Paris, France.; Département de Pharmacogénomique, Hôpital Saint Louis, AP-HP, F-75010 Paris, France., Lebbé C; INSERM, U976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010 Paris, France.; Université Paris Cité, Institut de Recherche Saint Louis (IRSL), F-75010 Paris, France.; Département de Dermatologie, Hôpital Saint Louis, AP-HP, F-75010 Paris, France., Dumaz N; INSERM, U976, Team 1, Human Immunology Pathophysiology & Immunotherapy (HIPI), F-75010 Paris, France.; Université Paris Cité, Institut de Recherche Saint Louis (IRSL), F-75010 Paris, France.
Publikováno v: Cancers [Cancers (Basel)] 2023 May 24; Vol. 15 (11). Date of Electronic Publication: 2023 May 24.
Zobrazit plný text záznamu
10
CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker
Autor: Alexandra Landras, Reger de Moura C, Céleste Lebbé, Suzanne Menashi, Fanélie Jouenne, Samia Mourah
Publikováno v: Cancers
Cancers, Vol 11, Iss 11, p 1803 (2019)
Microenvironment plays a crucial role in tumor development and progression. Cancer cells modulate the tumor microenvironment, which also contribute to resistance to therapy. Identifying biomarkers involved in tumorigenesis and cancer progression repr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73c2293e6660d38fefea157516da7c7b
https://pubmed.ncbi.nlm.nih.gov/31744072
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje